Issues for Surgery |
Risk of serotonin syndrome if continued (see Interaction(s) with Common Anaesthetic Agents and Interaction(s) with other Common Medicines used in the Perioperative Period). Risk of bleeding if continued (see Further Information). |
Advice in the Perioperative period |
Elective and Emergency Surgery Continue – check sodium levels pre-operatively (see Further Information). Post-operative Advice If a long nil by mouth (NBM) period is anticipated, or if there are concerns with enteral absorption, advice on alternative preparations / routes should be sought from a Psychiatrist. Monitor electrolytes, particularly sodium, if risk factors for hyponatraemia (see Further Information). |
Interaction(s) with Common Anaesthetic Agents |
CNS Excitation (Serotonin Syndrome) Some opioids act as weak serotonin reuptake inhibitors (SRIs) and can precipitate serotonin syndrome in conjunction with other serotonergic medication e.g. vortioxetine. Symptoms of serotonin syndrome may occur if vortioxetine is given concomitantly with1, 2: -
Patients should be monitored closely and the possibility of serotonin toxicity considered if patients experience altered mental state, autonomic dysfunction or neuromuscular adverse effects with concomitant treatment1. |
Interaction(s) with other Common Medicines used in the Perioperative Period |
CNS Excitation (Serotonin Syndrome) Opioids Methylthioninium Chloride (Methylene Blue) Other medications
Monitor patients for symptoms of serotonin syndrome such as fever, tremors, diarrhoea, and agitation. Concurrent treatment should be stopped if serotonin syndrome occurs1. Increased Risk of Bleeding (see also Further Information) Concomitant use of vortioxetine with other medications that can increase the risk of bleeding e.g. Non-Steroidal Anti-inflammatory Drugs (NSAIDs) may have an additive effect3, 4. Increased Risk of Hyponatraemia (see also Further Information) Concomitant use of SSRIs with NSAIDS may increase the risk of hyponatraemia1. |
Further Information |
Cessation of Treatment The manufacturer advises treatment can be stopped abruptly without need for gradual dose reduction1, 3, although transient withdrawal symptoms such as headache and muscle tension have been reported at higher doses4. Bleeding Serotonin released from platelets potentiates platelet aggregation. SSRIs can block platelet reuptake of serotonin from the bloodstream leading to serotonin depletion, impairment of haemostatic function and an increased risk of bleeding5. There are reports of prolonged bleeding time and / or bleeding abnormalities (gastrointestinal bleeding, gynaecological haemorrhages, ecchymoses, cutaneous or mucous bleedings) in patients receiving vortioxetine3. This risk is further increased with concomitant use of other medications known to affect platelet function3 (see Interaction(s) with other Common Medicines used in the Perioperative Period). Hyponatraemia Hyponatraemia, possibly as a result of inappropriate secretion of antidiuretic hormone has been associated with vortioxetine. Caution is required in patients at increased risk of hyponatraemia, such as elderly, or volume depleted / dehydrated patients or patients treated with diuretics3. |
References |
|